Search

Search Constraints

You searched for: Author/Creator Capotosti, Francesca

Search Results

1. [IC‐01–05]: FIRST‐IN‐HUMAN PET STUDIES WITH THE NEXT GENERATION TAU AGENT 18‐F PI‐2620 IN ALZHEIMER's DISEASE, PROGRESSIVE SUPRANUCLEAR PALSY, AND CONTROLS. (1st July 2017)

2. [IC‐P‐192]: PRECLINICAL CHARACTERIZATION OF PI‐2620, A NOVEL TAU PET TRACER FOR DETECTION OF TAU IN AD AND OTHER TAUOPATHIES. (1st July 2017)

3. [P2–381]: PRECLINICAL CHARACTERIZATION OF PI‐2620, A NOVEL TAU PET TRACER FOR DETECTION OF TAU IN AD AND OTHER TAUOPATHIES. (1st July 2017)

4. Developing a novel alpha‐synuclein positron emission tomography (PET) tracer for the diagnosis of synucleinopathies: Neuroimaging: Other neurodegenerative disorders. (7th December 2020)

5. Discovery of [18F]ACI‐12589, a Novel and Promising PET‐Tracer for Alpha‐Synuclein. (20th December 2022)

6. DT‐02‐06: NOVEL ALPHA‐SYNUCLEIN POSITRON EMISSION TOMOGRAPHY (PET) TRACERS FOR THE DIAGNOSIS OF PARKINSON'S DISEASE. (1st July 2006)

7. Initial clinical scans using [18F]ACI‐12589, a novel α‐synuclein PET‐tracer. (20th December 2022)

8. O2–06–04: A liposomal anti‐phospho‐tau vaccine demonstrates higher immunogenicity and specificity than a classical peptide vaccine approach. (1st July 2013)

9. O5‐06‐03: SMALL MOLECULES TARGETING TAU AGGREGATION DECREASE TAU PATHOLOGY AND NEUROINFLAMMATION IN VIVO. (1st July 2019)

10. Structure-activity relationship around PI-2620 highlights the importance of the nitrogen atom position in the tricyclic core. (15th December 2021)